Value of early using simvastatin in patients with acute coronary syndrome

Objective:To study whether the treatment of two different fortified dosage of Simvastatin in patients with acute coronary syndrome(ACS) is safe and may decrease the risk of major events in early period.Methord:One hundred and fifty-two patients with ACS, each of total cholesterol(TC) was over 4.68 mmol/L and low-densty lipoprotein cholesterol (LDL-C) over 2.6 mmol/L, were divided into three groups in random. Group A was control group ( n=51 ), Group B treated with Simvastatin 20 mg/d (n=51 ). Group C treated with Simvastatin 40 mg/d (n=50 ). The rate of eventual events ( angina, myocaridial infarction, re-hospitalization ), the level of serum lipid, the function of liver and renal and the reaction of adverse offects were surveyed during the period of one month and one year later. Result:During the period of one month and one year later, the rate of coronary disease events was decreased obviously in group B and C compared with group A (P 0.05). The mortality of group B decreased 3.92% and 7.84%. In one month and one year later compared with group A. The mortality of group C decreased 3.76% and 7.60% in one month and one year later. Group C compared with group B, the rate of angina and myocardial decreased (P 0.05 ). But the mortality had no significent difference between group B and C. The serum lipid also decreased obviously in group B and C after treatment. A few cases have the symptom of digestive system such as nausea and a few cases have the increased level of serum transaminase. They all come to normal level after decreasing dosage or creasing treatment. Conclusion:The treatment of Simvastatin 20 mg/d,40 mg/d to patients with early period of ACS is efficiency and safe. The treatment can decreased the rate of early cononary disease events. The efficiency is related with the dosage positively.